Generic Name: Tucatinib
Indications
-
HER2-Positive Breast Cancer: Indicated for use in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
-
HER2-Positive Colorectal Cancer: Indicated for use in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Dosage and Administration
-
Patient Selection: For patients with unresectable or metastatic colorectal cancer, confirm the presence of HER2 protein overexpression and RAS wild-type status in tumor specimens prior to initiating treatment.
-
Recommended Dosage: 300 mg orally twice daily. It may be taken with or without food.
-
Hepatic Impairment: For patients with severe hepatic impairment, the recommended dosage is 200 mg orally twice daily.
Specifications 150 mg/tablet, 60 tablets/box.
Contraindications None.
Reviews
There are no reviews yet.